Search

Displaying results 2621 - 2630 of 9322 in total
  1. Drug

    N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine

    go.drugbank.com/drugs/DB13948
    Experimental

    It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion [L1148]. It was discovered in 2014 at the University of Copenhagen.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  2. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    [L45424] The EMA approved this drug the following year, in February 2024, and Health Canada in March 2025 for the same condition. … [A257529] In February 2023, omaveloxolone was approved by the FDA for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.

  3. Drug

    Lanolin alcohols

    go.drugbank.com/drugs/DB14181
    Approved

    It is administered as an ointment base with topical insulin and has shown to be antagonistic to wound healing. It is commonly used in allergenic testing. … Lanolin alcohols are a complex combination of organic alcohols obtained by the hydrolysis of lanolin.

  4. Drug

    N-Acetylglucosamine

    go.drugbank.com/drugs/DB00141
    ApprovedInvestigationalNutraceutical

    The N-acetyl derivative of glucosamine.

  5. Drug

    Alclofenac

    go.drugbank.com/drugs/DB13167
    ApprovedWithdrawn

    It was withdrawn from the market in the United Kingdom in 1979.

  6. Drug

    Taliglucerase alfa

    go.drugbank.com/drugs/DB08876
    Approved

    Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. … It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.

  7. Drug

    Datopotamab deruxtecan

    go.drugbank.com/drugs/DB16410
    ApprovedInvestigational

    [L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623] … [L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer.

  8. Drug

    Ambenonium

    go.drugbank.com/drugs/DB01122
    ApprovedWithdrawn

    It is used in the management of myasthenia gravis.

  9. Drug

    Meclofenamic acid

    go.drugbank.com/drugs/DB00939
    ApprovedInvestigationalVet approved

    A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.

  10. Drug

    Magnesium trisilicate

    go.drugbank.com/drugs/DB09281
    Approved

    Magnesium trisilicate is an inorganic compound that is used as an antacid in the treatment of peptic ulcers.